Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine Sublingual in MDD
NCT01110902Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (3 arms), sponsored by Novartis. Primary endpoint: Change from Baseline to endpoint at Week 8 using the total score of the Hamilton Depression Rating Scale. Started May 2010; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01110902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110902.